| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Charles H. Lawrie | Q55292658 |
| Lorea Manterola | Q55459506 | ||
| Ibai Goicoechea | Q57551608 | ||
| Maria M Caffarel | Q58887967 | ||
| P2093 | author name string | María Arestin | |
| María Armesto | |||
| María Araiz | |||
| Marta Fernandez-Mercado | |||
| Erika Larrea | |||
| Carla Sole | |||
| Angela M Araujo | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells | Q21135545 | ||
| Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients | Q21143782 | ||
| Transfer of microRNAs by embryonic stem cell microvesicles | Q21143855 | ||
| Detection of microRNA expression in human peripheral blood microvesicles | Q21144210 | ||
| MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma | Q21245708 | ||
| Next-generation sequencing of microRNAs for breast cancer detection | Q21296770 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. | Q53416418 | ||
| Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. | Q53474457 | ||
| Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening. | Q53536512 | ||
| Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. | Q53556224 | ||
| Plasma miR-221/222 Family as Novel Descriptive and Prognostic Biomarkers for Glioma. | Q53624071 | ||
| Prognostic value of miR-106b expression in breast cancer patients. | Q53628965 | ||
| Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. | Q53656768 | ||
| U6 is not a suitable endogenous control for the quantification of circulating microRNAs. | Q54182683 | ||
| MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. | Q54191921 | ||
| Elevated level of microRNA-21 in the serum of patients with colorectal cancer. | Q54193071 | ||
| [Expression and clinical significance of plasma small RNA in patients with pancreatic cancer]. | Q54198756 | ||
| Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. | Q54229169 | ||
| A causal role for circulating miR-34b in osteosarcoma. | Q54242197 | ||
| Circulating microRNAs in the cerebrospinal fluid of patients with brain diseases. | Q54257764 | ||
| Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. | Q54261802 | ||
| Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. | Q54281886 | ||
| Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. | Q54296735 | ||
| Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. | Q54297101 | ||
| Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. | Q54300178 | ||
| Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. | Q54316362 | ||
| Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. | Q54339320 | ||
| Analysis of circulating microRNA: preanalytical and analytical challenges. | Q54378210 | ||
| Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. | Q54408211 | ||
| MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. | Q54424273 | ||
| Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. | Q54439228 | ||
| Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. | Q54456800 | ||
| Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. | Q54628347 | ||
| Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. | Q54775725 | ||
| miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. | Q54780999 | ||
| The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform | Q54997659 | ||
| Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. | Q34123686 | ||
| Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis | Q34125617 | ||
| Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression | Q34140780 | ||
| MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. | Q34179919 | ||
| Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 | ||
| The majority of microRNAs detectable in serum and saliva is concentrated in exosomes | Q34199626 | ||
| Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus | Q34224780 | ||
| miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions | Q34237504 | ||
| Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer | Q34241079 | ||
| Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients | Q34243908 | ||
| Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls | Q34251299 | ||
| Analysis of serum genome-wide microRNAs for breast cancer detection. | Q34258421 | ||
| MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. | Q34271306 | ||
| The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer | Q34273062 | ||
| Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies | Q34291952 | ||
| Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer | Q34310243 | ||
| miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs | Q34316535 | ||
| Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. | Q34328740 | ||
| Standardization of sample collection, isolation and analysis methods in extracellular vesicle research | Q34369038 | ||
| Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. | Q34384556 | ||
| microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. | Q34439377 | ||
| Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma | Q34441361 | ||
| Deregulation of serum microRNA expression is associated with cigarette smoking and lung cancer. | Q34441708 | ||
| Serum microRNA-155 as a potential biomarker to track disease in breast cancer | Q34447755 | ||
| MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1 | Q34455072 | ||
| Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma | Q34499638 | ||
| Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer | Q34526484 | ||
| miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer | Q34544501 | ||
| Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer | Q34591159 | ||
| Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia | Q34599349 | ||
| Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer | Q34613472 | ||
| Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer | Q34614989 | ||
| Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma | Q34655391 | ||
| Salivary microRNAs as promising biomarkers for detection of esophageal cancer | Q34656109 | ||
| Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells | Q24300024 | ||
| MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators | Q24336898 | ||
| miRBase: microRNA sequences, targets and gene nomenclature | Q24538656 | ||
| Characterization of extracellular circulating microRNA | Q24603537 | ||
| MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3 | Q24607952 | ||
| Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer | Q24609577 | ||
| Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 | ||
| The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence | Q24617045 | ||
| MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1) | Q24617676 | ||
| miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer | Q24630894 | ||
| let-7 Overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts | Q24644238 | ||
| The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer. | Q35919291 | ||
| Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma | Q35926157 | ||
| De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer | Q35927834 | ||
| MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways | Q35930474 | ||
| MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma | Q35943345 | ||
| Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. | Q35959203 | ||
| MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity | Q36010084 | ||
| Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals. | Q36057142 | ||
| Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia | Q36070308 | ||
| MicroRNAs in body fluids--the mix of hormones and biomarkers | Q36176435 | ||
| MicroRNA-125b functions as a tumor suppressor in hepatocellular carcinoma cells | Q36197303 | ||
| MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion | Q36215845 | ||
| Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia | Q36262865 | ||
| Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma | Q36294432 | ||
| Cell-free Circulating miRNA Biomarkers in Cancer | Q36316601 | ||
| Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer | Q36317309 | ||
| MicroRNA miR-16-1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells | Q36317789 | ||
| Folate status, folate-related genes and serum miR-21 expression: Implications for miR-21 as a biomarker | Q36324338 | ||
| Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool | Q36372817 | ||
| Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer | Q36388236 | ||
| miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. | Q36389324 | ||
| Detection of Exosomal miRNAs in the Plasma of Melanoma Patients | Q36409368 | ||
| miR-21 expression predicts prognosis in diffuse large B-cell lymphoma | Q36464776 | ||
| Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer | Q36498615 | ||
| Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma | Q36509109 | ||
| miR-34 miRNAs provide a barrier for somatic cell reprogramming | Q36522839 | ||
| Differential expression of miRNAs in the serum of patients with high-risk oral lesions | Q36530712 | ||
| Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5. | Q36545576 | ||
| MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway | Q36557155 | ||
| Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients | Q36563207 | ||
| Macrophage microvesicles induce macrophage differentiation and miR-223 transfer | Q36595322 | ||
| Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia | Q36630868 | ||
| MicroRNAs in vitreus humor from patients with ocular diseases | Q36634670 | ||
| Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells | Q24649539 | ||
| Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. | Q24651016 | ||
| Suppression of non-small cell lung tumor development by the let-7 microRNA family | Q24651985 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence | Q24652491 | ||
| Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 | ||
| miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation | Q24655473 | ||
| HuR recruits let-7/RISC to repress c-Myc expression | Q24657731 | ||
| Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation | Q24658400 | ||
| The tumor suppressor microRNA let-7 represses the HMGA2 oncogene | Q24681392 | ||
| Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction | Q26862733 | ||
| Extracellular microRNAs in urologic malignancies: chances and challenges | Q26866043 | ||
| MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma | Q27320938 | ||
| Prediction of mammalian microRNA targets | Q27860498 | ||
| RAS is regulated by the let-7 microRNA family | Q27860522 | ||
| An extensive class of small RNAs in Caenorhabditis elegans | Q27860626 | ||
| Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells | Q27860960 | ||
| MicroRNA expression profiles classify human cancers | Q28032481 | ||
| MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E | Q28117082 | ||
| Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma | Q28118779 | ||
| Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 | ||
| Tumour invasion and metastasis initiated by microRNA-10b in breast cancer | Q28131829 | ||
| let-7 microRNA functions as a potential growth suppressor in human colon cancer cells | Q28237683 | ||
| The let-7 microRNA represses cell proliferation pathways in human cells | Q28240833 | ||
| The role of let-7 in cell differentiation and cancer | Q28259549 | ||
| miRNA-34c regulates Notch signaling during bone development | Q28264397 | ||
| Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells | Q28277441 | ||
| let-7 regulates Dicer expression and constitutes a negative feedback loop | Q28290736 | ||
| The let-7 family of microRNAs | Q28293181 | ||
| The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors | Q28295428 | ||
| Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling | Q28297583 | ||
| Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system | Q28302231 | ||
| MicroRNA regulation of DNA repair gene expression in hypoxic stress | Q28306694 | ||
| miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma | Q39178990 | ||
| miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma | Q39181606 | ||
| Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. | Q39217323 | ||
| MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells | Q39251799 | ||
| The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. | Q39255444 | ||
| MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression | Q39274559 | ||
| miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma | Q39291006 | ||
| MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells | Q39292548 | ||
| MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. | Q39309630 | ||
| MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression | Q39314459 | ||
| Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. | Q39351138 | ||
| miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions | Q39364639 | ||
| miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer | Q39403567 | ||
| MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression | Q39403675 | ||
| miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. | Q39441445 | ||
| MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo | Q39447513 | ||
| Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients | Q39529523 | ||
| Regulation of vascular endothelial growth factor signaling by miR-200b. | Q39547800 | ||
| Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer | Q39577078 | ||
| miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells | Q39608849 | ||
| The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma | Q39621978 | ||
| MiR-125b targets BCL3 and suppresses ovarian cancer proliferation | Q39675974 | ||
| Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. | Q39706915 | ||
| Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells | Q39789168 | ||
| Differential profiling of human red blood cells during storage for 52 selected microRNAs | Q39900387 | ||
| Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. | Q39945284 | ||
| MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease | Q39950193 | ||
| Circulating microRNAs in plasma of patients with gastric cancers | Q39986294 | ||
| MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma | Q40135314 | ||
| Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors | Q40171554 | ||
| Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer | Q40178075 | ||
| Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer | Q40731890 | ||
| Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders | Q40787161 | ||
| Serum miR-200c expression level as a prognostic biomarker for gastric cancer | Q41054869 | ||
| MicroRNA-200c as a Prognostic Biomarker for Pancreatic Cancer | Q41193023 | ||
| RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants | Q41288716 | ||
| Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. | Q41377326 | ||
| Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus | Q41492063 | ||
| Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma | Q41530973 | ||
| Expression of serum let-7c, let-7i, and let-7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease | Q41570877 | ||
| Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3. | Q41680433 | ||
| Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma | Q41921103 | ||
| Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer | Q42112822 | ||
| An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions | Q42140417 | ||
| Expression and clinical significance of plasma microRNA-125b level in patients with oral squamous cell carcinoma | Q50437031 | ||
| Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. | Q50448025 | ||
| Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. | Q50924410 | ||
| MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. | Q51061144 | ||
| Neuroprotective effects of microRNA-210 against oxygen-glucose deprivation through inhibition of apoptosis in PC12 cells. | Q51065337 | ||
| Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. | Q51149290 | ||
| Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. | Q51535040 | ||
| Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells. | Q51582002 | ||
| MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. | Q52582850 | ||
| Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. | Q52843051 | ||
| Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. | Q52896892 | ||
| Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum. | Q52952354 | ||
| Salivary microRNAs in oral cancer. | Q52958113 | ||
| MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer. | Q52996440 | ||
| Upregulated miR-106a plays an oncogenic role in pancreatic cancer. | Q53071807 | ||
| Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. | Q53207870 | ||
| A novel serum microRNA panel to discriminate benign from malignant ovarian disease. | Q53227286 | ||
| Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. | Q53228625 | ||
| Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. | Q53228628 | ||
| Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. | Q53248858 | ||
| Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. | Q53253196 | ||
| Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. | Q53280056 | ||
| MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. | Q53295486 | ||
| [Chemotherapy with paclitaxel leads to microRNA release]. | Q53317976 | ||
| Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. | Q53356232 | ||
| The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer | Q35138997 | ||
| Circulating exosomal microRNAs as biomarkers of colon cancer. | Q35140085 | ||
| Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer | Q35145235 | ||
| Exosomes: secreted vesicles and intercellular communications | Q35161550 | ||
| The purple color reaction given by diphenylamine reagent. I. With normal and rheumatic fever sera | Q35186399 | ||
| miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. | Q35207623 | ||
| miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. | Q35238507 | ||
| Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma | Q35246395 | ||
| Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker | Q35247522 | ||
| Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma | Q35275041 | ||
| Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma | Q35473128 | ||
| Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer | Q35475974 | ||
| Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. | Q35518887 | ||
| MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma. | Q35551867 | ||
| Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer | Q35612605 | ||
| Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma | Q35633805 | ||
| miR-16 promotes the apoptosis of human cancer cells by targeting FEAT | Q35648747 | ||
| MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. | Q35672735 | ||
| Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer | Q35675384 | ||
| Salivary MicroRNA in Pancreatic Cancer Patients. | Q35677442 | ||
| miR-34 and p53: New Insights into a Complex Functional Relationship | Q35692651 | ||
| Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer | Q35740045 | ||
| An electrochemical nanobiosensor for plasma miRNA-155, based on graphene oxide and gold nanorod, for early detection of breast cancer. | Q35784691 | ||
| Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome | Q35802426 | ||
| Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? | Q35828512 | ||
| miR-155 targets Caspase-3 mRNA in activated macrophages | Q35843434 | ||
| Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA). | Q35856812 | ||
| Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer | Q35863159 | ||
| Circulating microRNAs in esophageal squamous cell carcinoma: association with locoregional staging and survival. | Q35870720 | ||
| Apoptosis and the target genes of microRNA-21. | Q35871493 | ||
| Changes in circulating microRNA levels associated with prostate cancer | Q35879858 | ||
| A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group | Q35902208 | ||
| MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells | Q36697933 | ||
| Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation | Q36706938 | ||
| MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer | Q36738904 | ||
| miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways | Q36772022 | ||
| Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. | Q36887378 | ||
| MicroRNA expression in lymphoma | Q36922250 | ||
| Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients--evidence of non-exosomal transport | Q36937666 | ||
| Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. | Q36942423 | ||
| Circulating miRNAs: cell-cell communication function? | Q36962750 | ||
| BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. | Q36964364 | ||
| Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma | Q37015623 | ||
| Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening | Q37026076 | ||
| Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma | Q37155033 | ||
| Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia | Q37188389 | ||
| MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma | Q37229396 | ||
| Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer | Q37279280 | ||
| Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma | Q37329665 | ||
| Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients | Q37394399 | ||
| High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer | Q37451898 | ||
| Tumour angiogenesis regulation by the miR-200 family | Q37523569 | ||
| Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. | Q37548836 | ||
| Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma | Q37548853 | ||
| Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer | Q37608685 | ||
| Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance | Q37618914 | ||
| Distinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis | Q37653084 | ||
| MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. | Q37993984 | ||
| Role of miR-155 in the regulation of lymphocyte immune function and disease. | Q38168572 | ||
| Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis. | Q38237787 | ||
| Circulating microRNA biomarker studies: pitfalls and potential solutions | Q38267750 | ||
| MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). | Q38303663 | ||
| Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. | Q38333929 | ||
| MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. | Q38336556 | ||
| Physiological roles of miR-155. | Q38398527 | ||
| Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs | Q38455097 | ||
| Membrane microparticles: shedding new light into cancer cell communication. | Q38569109 | ||
| The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment | Q38631508 | ||
| MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance | Q38663296 | ||
| Extracellular vesicle-mediated modulation of angiogenesis. | Q38667863 | ||
| Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer | Q38675709 | ||
| miR-30d Blocked Transforming Growth Factor β1-Induced Epithelial-Mesenchymal Transition by Targeting Snail in Ovarian Cancer Cells | Q38824925 | ||
| MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker | Q38839158 | ||
| miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer | Q38845695 | ||
| MiR-375 targets KLF4 and impacts the proliferation of colorectal carcinoma | Q38847978 | ||
| Suppression of miR-221 inhibits glioma cells proliferation and invasion via targeting SEMA3B. | Q38850720 | ||
| Augmented miR-10b expression associated with depressed expression of its target gene KLF4 involved in gastric carcinoma. | Q38851262 | ||
| MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. | Q38858232 | ||
| miR-155 regulative network in FLT3 mutated acute myeloid leukemia | Q38866003 | ||
| The Effects of miR-20a on p21: Two Mechanisms Blocking Growth Arrest in TGF-β-Responsive Colon Carcinoma. | Q38870781 | ||
| Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma | Q38876546 | ||
| MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin. | Q38878623 | ||
| Downregulation of miR-375 in aldosterone-producing adenomas promotes tumour cell growth via MTDH. | Q38878739 | ||
| MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin | Q38886948 | ||
| Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2. | Q38916685 | ||
| SHIP1 is targeted by miR-155 in acute myeloid leukemia | Q38961035 | ||
| Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. | Q38977396 | ||
| c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. | Q38987143 | ||
| Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer | Q38995808 | ||
| Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features | Q38996872 | ||
| Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. | Q39007403 | ||
| Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer | Q39015764 | ||
| Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. | Q39017421 | ||
| MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. | Q39033124 | ||
| Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer | Q39036116 | ||
| Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population | Q39036472 | ||
| microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma | Q39106292 | ||
| MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. | Q39139064 | ||
| Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma | Q39167703 | ||
| Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis | Q34693160 | ||
| MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. | Q34704824 | ||
| Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma | Q34713622 | ||
| MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy | Q34718910 | ||
| Individuality and variation in gene expression patterns in human blood | Q34762457 | ||
| Plasma processing conditions substantially influence circulating microRNA biomarker levels | Q34769479 | ||
| Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer | Q34775829 | ||
| Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. | Q34785335 | ||
| Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases | Q34785913 | ||
| Role of microRNAs in vascular diseases, inflammation, and angiogenesis | Q34786294 | ||
| Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein | Q34786521 | ||
| The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. | Q34806020 | ||
| Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer | Q34816422 | ||
| MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells | Q34842477 | ||
| Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis | Q34853050 | ||
| MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2 | Q34993681 | ||
| MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. | Q34995499 | ||
| Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection | Q34999442 | ||
| MicroRNA 29b functions in acute myeloid leukemia | Q35009142 | ||
| Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? | Q35010397 | ||
| Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer | Q35023641 | ||
| Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer | Q35040690 | ||
| Reduced expression levels of let-7c in human breast cancer patients | Q35042277 | ||
| MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway | Q35051948 | ||
| Suppression of transforming growth factor β receptor 2 and Smad5 is associated with high levels of microRNA miR-155 in the oral mucosa during chronic simian immunodeficiency virus infection | Q35076724 | ||
| Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies | Q35082591 | ||
| Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females | Q35088480 | ||
| A morphological study of retinal changes in unilateral amblyopia using optical coherence tomography image segmentation | Q35091710 | ||
| Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer | Q35093548 | ||
| RETRACTED: Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis | Q35097075 | ||
| Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R | Q35103309 | ||
| A critical evaluation of microRNA biomarkers in non-neoplastic disease | Q35107632 | ||
| Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma | Q35108381 | ||
| Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer | Q35110766 | ||
| Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma. | Q42150614 | ||
| Role of Notch signaling pathway in gastric cancer pathogenesis | Q42161527 | ||
| Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors | Q42833178 | ||
| Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis | Q42876911 | ||
| Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients | Q42956859 | ||
| Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury | Q43278313 | ||
| Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma | Q43879777 | ||
| Prognostic implications of serum microRNA-21 in colorectal cancer. | Q43937592 | ||
| Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer | Q44023844 | ||
| Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer | Q44030040 | ||
| Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. | Q44126830 | ||
| Extracellular miRNAs: the mystery of their origin and function | Q44235487 | ||
| A panel of five circulating microRNAs as potential biomarkers for prostate cancer | Q44430269 | ||
| Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients | Q44476266 | ||
| A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma | Q44481241 | ||
| Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer | Q44499697 | ||
| microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers | Q44586065 | ||
| miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells | Q44685681 | ||
| Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. | Q45202446 | ||
| Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer | Q45426468 | ||
| Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients | Q45729971 | ||
| Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. | Q45748068 | ||
| Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma | Q45836927 | ||
| Plasma post-operative miR-21 expression in the prognosis of gastric cancers | Q45888049 | ||
| Plasma microRNA, a potential biomarker for acute rejection after liver transplantation | Q46147230 | ||
| The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. | Q46198060 | ||
| Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer | Q46422776 | ||
| Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis | Q46477217 | ||
| MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin | Q48011302 | ||
| Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients | Q48409555 | ||
| Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. | Q55460538 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers | Q57230543 | ||
| miRNA profiling reveals a potential role of milk stasis in breast carcinogenesis | Q57630095 | ||
| Circulating miRNA Signatures: Promising Prognostic Tools for Cancer | Q57693485 | ||
| Germline mutation of microRNA-125a is associated with breast cancer | Q57828433 | ||
| Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia | Q60305981 | ||
| MicroRNAs modulate the angiogenic properties of HUVECs | Q62083234 | ||
| Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 | ||
| Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells | Q80019578 | ||
| Do platform-specific factors explain microRNA profiling disparities? | Q82315386 | ||
| High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer | Q83943983 | ||
| Circulating miRNAs are correlated with tumor progression in prostate cancer | Q84232903 | ||
| MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma | Q84449890 | ||
| Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells | Q84503442 | ||
| Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients | Q84561982 | ||
| Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis | Q84582500 | ||
| Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy | Q85032624 | ||
| Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma | Q85071854 | ||
| Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer | Q85209395 | ||
| MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5 | Q85753535 | ||
| Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma | Q85785866 | ||
| Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer | Q86028719 | ||
| Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening | Q86267440 | ||
| Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer | Q86397679 | ||
| Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors | Q86574422 | ||
| Lack of detectable oral bioavailability of plant microRNAs after feeding in mice | Q86698065 | ||
| Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma | Q87248595 | ||
| MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients | Q87252521 | ||
| Prognostic value of the microRNA-29 family in patients with primary osteosarcomas | Q87387709 | ||
| MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma | Q87929436 | ||
| Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma | Q87985149 | ||
| Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | Q88092055 | ||
| Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients | Q95393010 | ||
| Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer | Q95536716 | ||
| Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients | Q95567834 | ||
| Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases | Q34113528 | ||
| MicroRNAs and prostate cancer | Q34120269 | ||
| MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. | Q34120830 | ||
| ??? | Q94720111 | ||
| MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1 | Q28384675 | ||
| The Regulatory Role of MicroRNAs in EMT and Cancer | Q28391426 | ||
| Circulating MiR-125b as a marker predicting chemoresistance in breast cancer | Q28482362 | ||
| MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines | Q28748642 | ||
| MicroRNA biogenesis: coordinated cropping and dicing | Q29547496 | ||
| MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer | Q29547523 | ||
| Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma | Q29547772 | ||
| Export of microRNAs and microRNA-protective protein by mammalian cells | Q29614234 | ||
| MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer | Q29614237 | ||
| Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 | ||
| MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins | Q29615034 | ||
| The MicroRNA Spectrum in 12 Body Fluids | Q29618068 | ||
| Functional delivery of viral miRNAs via exosomes | Q29619574 | ||
| Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster | Q29620726 | ||
| Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. | Q31161472 | ||
| Characterization of salivary RNA by cDNA library analysis | Q33260959 | ||
| MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth | Q33326420 | ||
| Detection of cancer with serum miRNAs on an oligonucleotide microarray | Q33481633 | ||
| Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy | Q33572407 | ||
| Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer | Q33613644 | ||
| Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer | Q33654179 | ||
| miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression | Q33706171 | ||
| Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma | Q33736118 | ||
| microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma | Q33780259 | ||
| Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum | Q33824699 | ||
| Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma | Q33839512 | ||
| Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia | Q33862129 | ||
| SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells | Q33891236 | ||
| Genomewide Study of Salivary MicroRNAs for Detection of Oral Cancer. | Q33936552 | ||
| miR-221/222 control luminal breast cancer tumor progression by regulating different targets. | Q33952998 | ||
| MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. | Q33967256 | ||
| Purification and characterization of PCR-inhibitory components in blood cells | Q33971131 | ||
| microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer | Q34008192 | ||
| Haemolysis during sample preparation alters microRNA content of plasma. | Q34016595 | ||
| Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel | Q34066078 | ||
| miR-375 suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma | Q34092121 | ||
| MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta | Q34103001 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| biomarker | Q864574 | ||
| neoplasm | Q1216998 | ||
| liquid biopsy | Q22349364 | ||
| tumor biomarker | Q66205818 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 627 | |
| P577 | publication date | 2016-04-27 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies | |
| P478 | volume | 17 |
| Q36091092 | A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas |
| Q55470614 | A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. |
| Q89976378 | Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer |
| Q50015404 | Analysis of serum microRNA expression in male workers with occupational noise-induced hearing loss |
| Q90165630 | Automatic discovery of 100-miRNA signature for cancer classification using ensemble feature selection |
| Q64107195 | Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response |
| Q46306526 | Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks? |
| Q51028215 | Can nanotechnology improve cancer diagnosis through miRNA detection? |
| Q47113309 | Cell-to-cell communication: microRNAs as hormones |
| Q99591387 | Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application |
| Q47106247 | Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. |
| Q64097808 | Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies |
| Q58582706 | Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma |
| Q64892564 | Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients. |
| Q90664794 | Circulating miRNAs as Biomarker in Cancer |
| Q33713586 | Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner |
| Q93386513 | Clinical epigenetics: seizing opportunities for translation |
| Q41091907 | Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes |
| Q48241732 | Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression. |
| Q55251496 | Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E. |
| Q47216837 | Convenient Monitoring System of Intracellular microRNA Expression during Adipogenesis via Mechanical Stimulus-Induced Exocytosis of Lipovesicular miRNA Beacon |
| Q41183347 | Differential miR-346 and miR-582-3p Expression in Association with Selected Maternal and Fetal Complications |
| Q92596309 | Direct electrophoretic microRNA preparation from clinical samples using nanofilter membrane |
| Q92545395 | Entropy of mitochondrial DNA circulating in blood is associated with hepatocellular carcinoma |
| Q47939031 | Epigenetics: The Future Direction in Systemic Sclerosis |
| Q41369374 | Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder. |
| Q92255622 | Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy |
| Q90383404 | Extracellular miRNAs as Biomarkers of Head and Neck Cancer Progression and Metastasis |
| Q38867417 | Extracellular miRNAs as biomarkers in cancer |
| Q52647687 | Human salivary microRNAs in Cancer. |
| Q38716163 | Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children. |
| Q60922875 | Identification of Candidate miRNA Biomarkers for Glaucoma |
| Q38755836 | Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods |
| Q36375524 | Inflammation-related microRNA expression level in the bovine milk is affected by mastitis |
| Q33821481 | Making Meaningful Clinical Use of Biomarkers |
| Q38921098 | Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. |
| Q44385577 | Methods and novel technology for microRNA quantification in colorectal cancer screening. |
| Q41663220 | MicroRNA Signaling in Embryo Development. |
| Q42361202 | MicroRNAs as Biomarkers in Thyroid Carcinoma. |
| Q59358029 | MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma |
| Q88225399 | Molecular Profiling of Liquid Biopsy Samples for Precision Medicine |
| Q50097295 | Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. |
| Q92642131 | Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies |
| Q47359451 | Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma |
| Q90319523 | Prognostic and Predictive Epigenetic Biomarkers in Oncology |
| Q60046068 | Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation |
| Q92535893 | Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives |
| Q37210178 | Serum Levels of MicroRNA-206 and Novel Mini-STR Assays for Carrier Detection in Duchenne Muscular Dystrophy |
| Q58572333 | Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small-cell lung cancer |
| Q54918383 | Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. |
| Q47405806 | Serum, plasma and saliva biomarkers for head and neck cancer. |
| Q50063114 | Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks |
| Q57175219 | The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring |
| Q38681199 | The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance. |
| Q64098894 | The Roles of MicroRNA in Lung Cancer |
| Q47201290 | The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities |
| Q92256619 | Tumor-Derived Exosomes Mediate the Instability of Cadherins and Promote Tumor Progression |
| Q92378915 | Tumour biomarkers-Tracing the molecular function and clinical implication |
| Q47273844 | Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy |
| Q47668646 | Unpacking Major Depressive Disorder: From Classification to Treatment Selection |
| Q92022312 | Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study |
| Q89985584 | Validation of extracellular miRNA quantification in blood samples using RT-qPCR |
| Q39168132 | What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma? |
| Q41228775 | miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans |
| Q90414205 | miRNAs in the Diagnosis and Prognosis of Skin Cancer |
| Q47152593 | miRNAs, Melanoma and Microenvironment: An Intricate Network |
Search more.